Rejuvenate Biomed and SAS have announced a collaboration to develop an AI-driven, low-code drug repurposing discovery tool designed to expedite the identification of treatments for age-related diseases. The tool will be built on SAS Viya, a cloud-native AI and data platform, and aims to assist researchers in uncovering novel biological interactions through systematic analysis of biomedical data.
Dr. Ann Beliën, Founder and CEO of Rejuvenate Biomed, stated, “By embracing this partnership and leveraging the capabilities of SAS Viya, we expect to meaningfully de-risk and accelerate the development of our internal portfolio while enhancing our discovery platform and partnering capabilities.”
Rejuvenate Biomed is a clinical-stage biotechnology company developing therapeutics targeting the root causes of age-related diseases. Utilizing two proprietary drug discovery platforms, CombinAge™ and CelegAge™, the company has built a pipeline of five unique combination drugs addressing various age-related conditions, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative indications.
The partnership aims to equip Rejuvenate Biomed with advanced tools and technology to further develop and scale its drug discovery platform and pipeline.
